Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Estrogen receptor-positive (ER+) breast cancers (BC) cause death despite well-established treatments. MicroRNAs (miRNAs) have potential as biomarkers specific to cancer subtypes and tissues, therefore miRNA-based biomarkers could help improve patient survival. In this study, we investigated a relatively unknown miRNA, miR-7974. We utilized small RNA data from 204 breast tissue samples to study miR-7974 association with clinicopathological features and outcomes for BC patients. Additionally, in vitro and in ovo methods were used to identify miR-7974 role at molecular and cellular level in MCF-7 cells. Findings were validated using MDA-MB-453 cells. MiR-7974 was upregulated in many clinicopathological features of BC (P<0.05). Furthermore, the highest expression of miR-7974 was associated with poor relapse-free survival in ER+ BC patients [hazard ratio (HR)=8.70; 95% confidence interval (CI)=3.28-23.06; P=1.37x10-05] and poor BC-specific survival in patients receiving only surgical treatment (HR=8.36; 95% CI=1.01-69.06; P=0.049). Our studies revealed that miR-7974 targets autophagy gene, MAP1LC3B, identified as direct miR-7974 target (P<0.05) in MCF-7 cells. In vitro analyses indicated overexpressing miR-7974 had anti-proliferative effect in MCF7 and MDA-MB-453 cells. Overall, our results demonstrate potential prognostic role of miR-7974 in ER+ BC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040258PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0322179PLOS

Publication Analysis

Top Keywords

estrogen receptor-positive
8
clinicopathological features
8
mir-7974
5
high expression
4
expression mir-7974
4
mir-7974 predicts
4
predicts poor
4
poor prognosis
4
prognosis associated
4
associated autophagy
4

Similar Publications

Background: Although some studies have indicated that CDK4/6 inhibitors are beneficial for the progression-free survival (PFS) and overall survival (OS) in breast cancer, evidence regarding the assessment of clinical response remains insufficient. Therefore, this study aims not only to evaluate the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR(+)/HER2(-) metastatic breast cancer, but also to analyze the objective response rate (ORR) and clinical benefit rate (CBR), providing comprehensive clinical outcome insights.

Materials And Methods: A literature search was performed in PubMed, Embase, Cochrane Library, and ClinicalTrials.

View Article and Find Full Text PDF

ROLE OF PHTHALATES IN BREAST CANCER INITIATION, PROGRESSION AND DRUG RERSISTANCE: a scoping review and recommendations.

Toxicol Lett

September 2025

Gynecologic and Breast Oncologic Surgery Department, European Hospital Georges Pompidou, APHP, Paris, France; Departement of environnemental toxicology, Université Paris Cité, INSERM UMR-S 1124, Paris.

Phthalates are endocrine-disrupting chemicals (EDCs) with implications in breast cancer (BC). This review synthesizes epidemiological and experimental data to evaluate the role of phthalates in BC initiation, progression, and therapeutic resistance. We performed a scoping review using bibliographic citations from PubMed, Clinical Trials.

View Article and Find Full Text PDF

Distinct clinical outcomes according to molecular subgroups in relapsed endometrial carcinoma: A cohort study.

Gynecol Oncol

September 2025

Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Pathology, Helsinki University Hospital and Research Program in Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Objective: This study evaluated time to progression and post-recurrence disease-specific survival in molecularly classified endometrial carcinoma to improve understanding of disease biology and factors influencing tumor aggressiveness.

Methods: In this retrospective cohort study, immunohistochemistry and polymerase-ϵ (POLE) sequencing were used for molecular classification and determination of estrogen receptor and programmed death-ligand 1 (PD-L1) expression.

Results: We identified 1146 patients with molecularly classified endometrial carcinoma, of whom 220 (19.

View Article and Find Full Text PDF

Coalescing single-cell genomes and transcriptomes to decode breast cancer progression.

Cell

August 2025

Department of Systems Biology, UT MD Anderson Cancer Center, Houston, TX 77030, USA; MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA; Department of Bioinformatics, UT MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

Understanding epithelial lineages of breast cancer and genotype-phenotype relationships requires direct measurements of the genome and transcriptome of the same single cells at scale. To achieve this, we developed wellDR-seq, a high-genomic-resolution, high-throughput method to simultaneously profile the genome and transcriptome of thousands of single cells. We profiled 33,646 single cells from 12 estrogen-receptor-positive breast cancers and identified ancestral subclones in multiple patients that showed a luminal hormone-responsive lineage, indicating a potential cell of origin.

View Article and Find Full Text PDF

CDK4/6 inhibitors (CDK4/6i) improve outcome in patients with advanced estrogen receptor-positive, HER2 breast cancer. The phase 3 SONIA trial compared the addition of CDK4/6i to first- versus second-line endocrine therapy for time to disease progression after second-line treatment (progression-free survival after two lines of treatment (PFS2)), as well as for secondary outcomes overall survival, PFS after one line of treatment (PFS1), health-related quality of life (HRQOL), toxicity and cost-effectiveness. No significant difference in PFS2 was observed; however, on an individual patient level this may be different.

View Article and Find Full Text PDF